CD1D and plasma cell myeloma: In trial NCT04754100, donor-derived, pure, unedited iNKT cell products, manufactured and cryopreserved ahead of demand, were administered to unrelated and non-lymphodepleted patients with relapsed/refractory multiple myeloma, known to express CD1d (104).